24-week Open-label Extension Study Evaluating the Effect of PXT00864 in Mild Alzheimer's Disease Patients Further to PLEODIAL-I Completion

Trial Profile

24-week Open-label Extension Study Evaluating the Effect of PXT00864 in Mild Alzheimer's Disease Patients Further to PLEODIAL-I Completion

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Jul 2017

At a glance

  • Drugs Acamprosate/baclofen (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PLEODIAL-II
  • Sponsors Pharnext
  • Most Recent Events

    • 20 Jul 2017 Results from PLEODIAL clinical trial (this study and NCT02361424), presented at the Alzheimer's Association International Conference 2017
    • 13 Dec 2016 Results published in the Pharnext Media Release.
    • 13 Dec 2016 According to a Pharnext media release, data from PLEODIAL clinical trial (this study and CTP 253068) presented at the 9th Clinical Trials on Alzheime's Disease (CTAD) conference.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top